 | Up a level |
Fujioka, Ken, O'Neil, Patrick M, Davies, Melanie, Greenway, Frank, Lau, David CW, Claudius, Birgitte, Skjoth, Trine Vang, Jensen, Christine Bjorn and Wilding, John PH 
ORCID: 0000-0003-2839-8404
(2016)
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
OBESITY, 24 (11).
pp. 2278-2288.
O'Neil, Patrick M, Birkenfeld, Andreas L, McGowan, Barbara, Mosenzon, Ofri, Pedersen, Sue D, Wharton, Sean, Carson, Charlotte Giwercman, Jepsen, Cecilie Heerdegen, Kabisch, Maria and Wilding, John PH ORCID: 0000-0003-2839-8404
(2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
LANCET, 392 (10148).
pp. 637-649.
O'Neil, Patrick M, Aroda, Vanita R, Astrup, Arne, Kushner, Robert, Lau, David CW, Wadden, Thomas A, Brett, Jason, Cancino, Ana-Paula and Wilding, John PH ORCID: 0000-0003-2839-8404
(2017)
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
DIABETES OBESITY & METABOLISM, 19 (11).
pp. 1529-1536.